UNITED KINGDOM – Merk & Co’s checkpoint inhibitor Keytruda, which has been available for three years through the Cancer Drugs Fund (CDF), has now been approved for routine NHS use…
Read More
FRANCE – In a deal worth up to US$5.2 billion in milestone payments, French drugmaker Sanofi will collaborate with British AI firm Exscientia Plc to develop up to 15 drug…
Read More
USA – US Food and Drug Administration (USFDA) has approved Merck & Co.’s immunotherapy Keytruda for use in early kidney cancer, making it the first treatment of its kind available…
Read More
UNITED KINGDOM – Exscientia’s initial public offering and private placement has raised US$464 million to fund its artificial intelligence-based approach to drug discovery and development. The new cash infusion follows…
Read More